00:00 Elisio's proprietary Amphiphile, or AMP, platform differentiates the company through
00:06 the development of cancer immunotherapies for patients with limited treatment options
00:10 and often poor outcomes.
00:12 As the foundation for the various vaccine candidates in the biotech company's pipeline,
00:15 the AMP platform will help Elisio combat cancer and other diseases.
00:20 The platform was first developed in the lab of Daryl Irvine, PhD, whose work as a Howard
00:24 Hughes Medical Institute investigator and professor at the Koch Institute for Integrative
00:28 Cancer Research at MIT has put him at the forefront of the field.
00:32 A clinical-stage biotechnology company, Elisio Therapeutics has developed multiple cancer
00:36 vaccine candidates, including ELI002 for CRAS-driven cancers caused by a mutation of the CRAS
00:42 gene, ELI007 for cancers involving mutant BRAF gene, and ELI008 for cancers involving
00:48 p53 hotspot mutations.
00:50 Preclinical trials have shown that Amphiphiles target and concentrate an array of different
00:54 immunogens in the lymph nodes, resulting in tumor or pathogen-targeted immunity.
00:59 And one trial on Elisio Therapeutics' vaccine was given to patients with pancreatic and
01:03 colorectal cancers.
01:04 The results were promising, with 77% of patients experiencing a reduction in biomarkers that
01:09 show the persistence of tumors.
01:11 32% of patients completely cleared those biomarkers.
01:14 Elisio Therapeutics seems to be leading the charge towards vaccination against cancer.
01:18 By combining expertise in immunology and immunotherapy, Elisio is precisely targeting and fully engaging
01:24 the lymph nodes, the site in our bodies where the immune response to cancer is orchestrated.
01:28 (upbeat music)
Comments